30 closest matches · ranked by relevance
Hyperemesis Gravidarum
Primary: Baseline Adjusted Mean Daily Motherisk-PUQE Total Scores (Pregnancy-unique Quantification of Emesis and Nausea Scale) for Days 5-7 — 6.35; 13.22 units on a scale — p=0.01
Hyperemesis Gravidarum · Pregnancy Related
Primary: Blood Cholecystokinin (CCK) Levels — 53.13; 54.55; 73.61; 81.24 picogram/mililiters (pg/ml) — p=0.05
Hyperemesis Gravidarum · Nausea Gravidarum · Vomiting of Pregnancy
Primary: Time to Symptom Control — 72; 87 minutes
Hyperemesis Gravidarum
Primary: PUQE Score for Assessment of Severity in Hyperemesis Gravidarum — 6.3; 8.5 units on a scale — p=0.001
Chronic Unexplained Nausea and Vomiting · Gastroparesis
Primary: Average Daily Use of Rescue Medications for Exacerbation of Nausea/Vomiting. — 1.186; 0.551; 0.754; 0.447 medications/day
Pregnancy · Cesarean Section · Aspiration
Primary: Change in Gastric Volume (mL) — -1; -2; 0; 1 Milliliters — p=.001
Gastroparesis
Primary: Number of Participants With Improvement in Nausea — 29; 25 participants — p=0.43
Obesity
Primary: Weight Gain Per Week of Observation — 0.39; 0.33 kg/wk
Chemotherapy-Induced Nausea and Vomiting
Primary: Percentage of Patients With Complete Control — 71.4; 76.0; 90.9 Percentage
Nausea and Vomiting of Pregnancy
Primary: Diclectin Versus Placebo for Treatment of Nausea and Vomiting of Pregnancy (NVP) as Measured by the Change in Pregnancy Unique-Quantification of Emesis (PUQE) Overall…
Pre-Eclampsia · Hypertension in Pregnancy · Obesity
Primary: Number of Participants With Preeclampsia Diagnosis With Severe Features Based on Clinician Diagnosis — 37; 41 Participants
Cyclic Vomiting Syndrome
Primary: The Number of Vomiting/Retching Events Reported by Study Participants Following Treatment/Dosing During the Home Treament Period. — 0.69; 1.43; 1.33; 1.48 event — p=0.7024
Overweight and Obesity · Physical Activity · Weight Change, Body
Primary: Gestational Weight Change — 6.9; 8.8 kilograms
Post-operative Nausea and Vomiting · Laparoscopic Sleeve Gastrectomy
Primary: Number of Participants With PONV-related Delay of Hospital Discharge — 0; 4 Participants
Energy Intake · Energy Expenditure
Primary: Energy Intake — 2908; 2698; 2581 kilocalories per day
Gestational Diabetes · Obesity
Primary: Number of Participants With a Composite Perinatal Outcome — 235; 261 Participants
Nausea · Vomiting
Primary: Occurrence of Intra-operative and Post-operative Vomiting — 30; 45 Participants — p=0.07
Ovarian Cancer · Uterine Cancer
Primary: Overall Complete Response Rate — 10; 10 percentage of participants
Drug-induced Nausea and Vomiting
Primary: Number of Participants Experiencing Symptoms — 45; 19 Participants — p=0.00
Nausea · Vomiting · Satisfaction
Primary: Nausea — 44; 14; 22 Participants — p=< 0.00001
Obesity · Weight Gain, Maternal
Primary: Percent Change in Body Weight — 10.9; 9.6 percentage change
Pregnancy Complications · Obesity · Pre-Eclampsia
Primary: Oral Glucose Insulin Sensitivity (OGIS) Index — 405.0; 426.0; 418.9 uU/mL
Gestational Diabetes Mellitus
Primary: Glycemic Control by Measurement of HbA1c — 5.17; 5.57 mean percentage
Diabetes
Primary: Gestational Weight Gain — 7.9; 10.4 kg
Pregnancy Induced Hypertension · Superimposed Preeclampsia · Hypertension
Primary: Number of Participants With Adverse Events — 2; 0 participants
Nausea · Extrapyramidal Symptoms
Primary: Nausea Scale — 0; 0; 0; 0 units on a scale
Gestational Diabetes
Primary: Primary Composite Outcome — 150; 167 Participants — p=0.13
Obesity · Pregnancy
Primary: Maternal Weight Change — 1.2; -2.6 kg
Chemotherapy-induced Nausea and Vomiting
Primary: Delayed Phase Complete Response (CR) Rate — 64.7; 56.6 percentage of participants
Postoperative Nausea and Vomiting
Primary: The Incidence of Postoperative Nausea and Vomiting — 5; 18 Participants — p=<0.05